AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 75 |
Market Cap | 11.98B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 0.62 |
PE Ratio (ttm) | 141.95 |
Forward PE | n/a |
Analyst | Buy |
Ask | 92 |
Volume | 872,800 |
Avg. Volume (20D) | 1,004,785 |
Open | 87.55 |
Previous Close | 87.18 |
Day's Range | 86.45 - 88.52 |
52-Week Range | 49.33 - 90.48 |
Beta | undefined |
About GMED
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion p...
Analyst Forecast
According to 12 analyst ratings, the average rating for GMED stock is "Buy." The 12-month stock price forecast is $94, which is an increase of 6.81% from the latest price.
Next Earnings Release
Analysts project revenue of $642.82M, reflecting a 4.26% YoY growth and earnings per share of 0.73, making a 21.67% increase YoY.